Asthma Control and Management Changes in Japan: Questionnaire Survey

被引:16
作者
Hasegawa, Takashi [1 ]
Koya, Toshiyuki [2 ]
Sakagami, Takuro [2 ]
Toyabe, Shinichi [3 ]
Kagamu, Hiroshi [2 ]
Arakawa, Masaaki [2 ]
Gejyo, Fumitake [2 ]
Narita, Ichiei [2 ]
Suzuki, Eiichi [1 ]
机构
[1] Niigata Univ, Med & Dent Hosp, Dept Gen Med, Niigata 95021, Japan
[2] Niigata Univ, Grad Sch Med & Dent Sci, Div Resp Med, Niigata 95021, Japan
[3] Niigata Univ, Med & Dent Hosp, Dept Patient Safety, Niigata 95021, Japan
关键词
asthma; control; inhaled corticosteroid; questionnaire survey; THEOPHYLLINE; DRUG; EXACERBATION; MONTELUKAST; GUIDELINES; THERAPY;
D O I
10.2169/internalmedicine.51.6586
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Despite the advances of asthma management and the accompanying improved asthma control, many problems related to asthma management still remain. The Niigata Asthma Treatment Study Group has been regularly collecting information via surveys since 1998 using a questionnaire, on problems related to asthma management; various studies on asthma management have been reported using data from the questionnaire. Methods The aim of this study was to investigate the changes in asthma control and management for every two-year period using the data from 1998 to 2008; future problems requiring resolution were extracted and discussed. Results The number of cases surveyed each year was about 3,000 (2,593-3,347 cases). The changes in the data from 1998 to 2008, including asthma attacks and symptoms rate, indicated the improvement of asthma control with the spread of medication according to the guidelines; of particular note, there was a 24.1% increase in the usage rate of inhaled corticosteroids during the study period. From 2002 to 2008, however, some asthmatic conditions seemed to show no improvement with regards to asthma control related to the rates of changes in peak flow meter use, leukotriene receptor antagonist use and oral sustained-released theophylline use. Moreover, there was no decrease in the occurrence of emergency episodes related to asthma deaths. Conclusion In the actual clinical setting, asthma control seems to be progressing well with the appropriate changes of medication according to the guidelines, and in part due to inhaled corticosteroid use. However, there were two problems which need to be addressed: 1) no improvement in some asthmatic conditions and 2) the occurrence of emergency episodes related to asthma deaths. In the future, it will be necessary to manage asthma in view of these points.
引用
收藏
页码:567 / 574
页数:8
相关论文
共 27 条
[1]  
[Anonymous], 2007, J ALLERGY CLIN IMM S, V120, pS94
[2]  
Arioka H., 2005, Allergol Int, V54, P10, DOI [10.2332/allergolint.54.473, DOI 10.2332/ALLERGOLINT.54.473]
[3]   Theophylline - New perspectives for an old drug [J].
Barnes, PJ .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (06) :813-818
[4]   Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial [J].
Bjermer, L ;
Bisgaard, H ;
Bousquet, J ;
Fabbri, LM ;
Greening, AP ;
Haahtela, T ;
Holgate, ST ;
Picado, C ;
Menten, J ;
Dass, SB ;
Leff, JA ;
Polos, PG .
BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7420) :891-895
[5]  
Currie GP, 2005, CHEST, V128, P2954, DOI 10.1378/chest.128.4.2954
[6]  
HASEGAWA T, 2005, ALLERGOL INT, V54, P555
[7]  
Hasegawa Takashi, 2004, Allergology International, V53, P145, DOI 10.1111/j.1440-1592.2004.00311.x
[8]  
Koyanagi Kumiko, 2009, Allergology International, V58, P519, DOI 10.2332/allergolint.09-OA-0095
[9]   Global Initiative for Asthma (GINA) guidelines: 15 years of application [J].
Kroegel, Claus .
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2009, 5 (03) :239-249
[10]   Asthma control in the Asia-Pacific region: The asthma insights and reality in Asia-Pacific study [J].
Lai, CKW ;
de Guia, TS ;
Kim, YY ;
Kuo, SH ;
Mukhopadhyay, A ;
Soriano, JB ;
Trung, PL ;
Zhong, NS ;
Zainudin, N ;
Zainudin, BMZ .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2003, 111 (02) :263-268